Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Relapsed Polymyalgia Rheumatica
NCT05767034Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of secukinumab in polymyalgia rheumatica (PMR), sponsored by Novartis. Started Mar 2023; status: completed.
02
Drugs
secukinumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT05767034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767034.